{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:13:34Z","timestamp":1781306014471,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bmcl.2021.128333","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T01:52:10Z","timestamp":1629337930000},"page":"128333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors"],"prefix":"10.1016","volume":"50","author":[{"given":"Sven","family":"Ullrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu M.","family":"Sasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun C.","family":"Mahawaththa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasuni B.","family":"Ekanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Morewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josemon","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shuttleworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy","family":"Whitefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Otting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bmcl.2021.128333_b0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10278","key":"10.1016\/j.bmcl.2021.128333_b0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128333_b0015","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/ijms21082839","article-title":"COVID-19 drug discovery using intensive approaches","volume":"21","author":"Asai","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128333_b0020","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/med.21475","article-title":"Proteases and protease inhibitors in infectious diseases","volume":"38","author":"Agbowuro","year":"2018","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128333_b0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.antiviral.2013.08.015","article-title":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses","volume":"100","author":"Hilgenfeld","year":"2013","journal-title":"Antiviral Res"},{"issue":"18","key":"10.1016\/j.bmcl.2021.128333_b0030","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J"},{"issue":"17","key":"10.1016\/j.bmcl.2021.128333_b0035","doi-asserted-by":"crossref","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128333_b0040","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J Gen Virol"},{"key":"10.1016\/j.bmcl.2021.128333_b0045","article-title":"Homology models of coronavirus 2019-nCoV 3CLpro protease","author":"Stoermer","year":"2020","journal-title":"ChemRxiv"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128333_b0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128333_b0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128333_b0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"14","key":"10.1016\/j.bmcl.2021.128333_b0065","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128333_b0070","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/v10120721","article-title":"Development of small-molecule MERS-CoV inhibitors","volume":"10","author":"Liang","year":"2018","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128333_b0075","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol"},{"issue":"21","key":"10.1016\/j.bmcl.2021.128333_b0080","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1016\/j.bmcl.2007.08.031","article-title":"Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors","volume":"17","author":"Ghosh","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"10.1016\/j.bmcl.2021.128333_b0085","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1021\/jm050548m","article-title":"Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease Inhibitors","volume":"48","author":"Ghosh","year":"2005","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128333_b0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s13238-013-2841-3","article-title":"The newly emerged SARS-like coronavirus HCoV-EMC also has an 'Achilles\u2019 heel': current effective inhibitor targeting a 3C-like protease","volume":"4","author":"Ren","year":"2013","journal-title":"Protein Cell."},{"issue":"17","key":"10.1016\/j.bmcl.2021.128333_b0095","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","article-title":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic \u03b1, \u03b2-unsaturated esters","volume":"13","author":"Shie","year":"2005","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"10.1016\/j.bmcl.2021.128333_b0100","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure\u2212activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128333_b0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmcl.2021.128333_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2017.02.007","article-title":"Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLpro inhibitors","volume":"141","author":"Kumar","year":"2017","journal-title":"Antiviral Res"},{"issue":"21","key":"10.1016\/j.bmcl.2021.128333_b0115","doi-asserted-by":"crossref","first-page":"9400","DOI":"10.1016\/j.bmc.2008.09.057","article-title":"Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant","volume":"16","author":"Akaji","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"10.1016\/j.bmcl.2021.128333_b0120","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1021\/jm200870n","article-title":"Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors","volume":"54","author":"Akaji","year":"2011","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128333_b0125","doi-asserted-by":"crossref","first-page":"e1005531","DOI":"10.1371\/journal.ppat.1005531","article-title":"Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor","volume":"12","author":"Kim","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2021.128333_b0130","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2018.03.004","article-title":"Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element","volume":"150","author":"Galasiti Kankanamalage","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128333_b0135","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2021.128333_b0140","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1016\/j.bmcl.2005.09.012","article-title":"Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor","volume":"15","author":"Martina","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128333_b0145","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jmb.2006.11.078","article-title":"Crystal structures reveal an induced-fit binding of a substrate-like aza-peptide epoxide to SARS coronavirus main peptidase","volume":"366","author":"Lee","year":"2007","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128333_b0150","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/jm0507678","article-title":"Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors","volume":"49","author":"Zhang","year":"2006","journal-title":"J Med Chem"},{"issue":"36","key":"10.1016\/j.bmcl.2021.128333_b0155","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1016\/j.tet.2006.06.052","article-title":"Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors","volume":"62","author":"Sydnes","year":"2006","journal-title":"Tetrahedron"},{"issue":"7811","key":"10.1016\/j.bmcl.2021.128333_b0160","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"6497","key":"10.1016\/j.bmcl.2021.128333_b0165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"issue":"6536","key":"10.1016\/j.bmcl.2021.128333_b0170","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128333_b0175","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"issue":"6489","key":"10.1016\/j.bmcl.2021.128333_b0180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.bmcl.2021.128333_b0185","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1002\/anie.202016961","article-title":"Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors","volume":"60","author":"Breidenbach","year":"2021","journal-title":"Angew Chem Int Ed"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128333_b0190","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsinfecdis.0c00815","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","volume":"7","author":"Steuten","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2021.128333_b0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr Opin Virol."},{"key":"10.1016\/j.bmcl.2021.128333_b0200","doi-asserted-by":"crossref","first-page":"113530","DOI":"10.1016\/j.ejmech.2021.113530","article-title":"A cyclic peptide inhibitor of the SARS-CoV-2 main protease","volume":"221","author":"Kreutzer","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"23","key":"10.1016\/j.bmcl.2021.128333_b0205","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1021\/jm501412a","article-title":"Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors","volume":"57","author":"Flanagan","year":"2014","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128333_b0210","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1021\/acs.orglett.9b01545","article-title":"Biocompatible macrocyclization between cysteine and 2-cyanopyridine generates stable peptide inhibitors","volume":"21","author":"Nitsche","year":"2019","journal-title":"Org Lett"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128333_b0215","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1039\/D0SC05125J","article-title":"A biocompatible stapling reaction for in situ generation of constrained peptides","volume":"12","author":"Morewood","year":"2021","journal-title":"Chem Sci"},{"issue":"15","key":"10.1016\/j.bmcl.2021.128333_b0220","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/cmdc.202000237","article-title":"Structure-based macrocyclization of substrate analogue NS2B-NS3 protease inhibitors of Zika, West Nile and dengue viruses","volume":"15","author":"Braun","year":"2020","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.bmcl.2021.128333_b0225","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1021\/acsmedchemlett.0c00657","article-title":"2-Cyanoisonicotinamide conjugation: a facile approach to generate potent peptide inhibitors of the Zika virus protease","volume":"12","author":"Patil","year":"2021","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128333_b0230","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/prot.23106","article-title":"The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling","volume":"79","author":"Li","year":"2011","journal-title":"Proteins"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128333_b0235","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128333_b0240","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02577-20","article-title":"Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2","volume":"65","author":"Kuo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128333_b0245","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2202-9-S3-S7","article-title":"Requirements for a lead compound to become a clinical candidate","volume":"9","author":"Hefti","year":"2008","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128333_b0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/ar700109k","article-title":"Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection","volume":"41","author":"Njoroge","year":"2008","journal-title":"Acc Chem Res"},{"issue":"11","key":"10.1016\/j.bmcl.2021.128333_b0255","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nbt.2020","article-title":"Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus","volume":"29","author":"Kwong","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.bmcl.2021.128333_b0260","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/AAC.00787-10","article-title":"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease","volume":"54","author":"White","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.bmcl.2021.128333_b0265","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","article-title":"Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A protease","volume":"57","author":"Jiang","year":"2014","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128333_b0270","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1039\/C6CC06951G","article-title":"A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets","volume":"53","author":"Passioura","year":"2017","journal-title":"Chem Commun"},{"key":"10.1016\/j.bmcl.2021.128333_b0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fmolb.2015.00056","article-title":"A script to highlight hydrophobicity and charge on protein surfaces","volume":"2","author":"Hagemans","year":"2015","journal-title":"Front Mol Biosci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21005606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21005606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:41:39Z","timestamp":1760773299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21005606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":55,"alternative-id":["S0960894X21005606"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128333","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128333"}}